{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020009","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.674953+00:00","generated_at":"2026-06-03T00:40:02.154668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vir Biotechnology Q1 net loss narrows to $65.3M; CFO stepping down; pipeline catalysts ahead","bullets":["Net loss of $65.3M ($0.48 loss per share) vs $140.9M ($1.06) in Q1 2023; revenue $56.4M down 10.5% YoY.","Cash, equivalents & investments $1.51B, down $118M in Q1; FY2024 R&D+SG&A guidance reaffirmed $650-680M.","CFO Sung Lee stepping down effective May 3; successor search initiated.","SOLSTICE hepatitis delta late-breaker abstract accepted at EASL June; 24-week data expected Q4 2024.","MARCH hepatitis B data and HIV VIR-1388 immunogenicity data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020009","json":"https://secwatch.observer/filing/0001628280-24-020009.json","markdown":"https://secwatch.observer/filing/0001628280-24-020009.md","text":"https://secwatch.observer/filing/0001628280-24-020009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/0001628280-24-020009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/vir-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:40:02.154668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b7eb831445445a0398f94a2f7fea94f4b9f81fa","claim":"Vir Biotechnology, Inc. reported first quarter ended March 31, 2024 results: revenue $56.4 million.","evidence_excerpt":"cash equivalents and investments declined by approximately $118 million during the first quarter of 2024. Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023. Revenues were comprised of the following components: Three Months Ended March 31, 2024 2023 % Change (in millions)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/0001628280-24-020009-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$56.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}